137 related articles for article (PubMed ID: 29319843)
41. Optimal vancomycin doses for methicillin-resistant Staphylococcus aureus infection in urological renal dysfunction patients.
Shigemura K; Osawa K; Yamamichi F; Tanaka K; Tokimatsu I; Arakawa S; Fujisawa M
Int Urol Nephrol; 2015 Jun; 47(6):887-91. PubMed ID: 25899764
[TBL] [Abstract][Full Text] [Related]
42. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
43. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
Eiland LS; English TM; Eiland EH
Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
[TBL] [Abstract][Full Text] [Related]
44. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.
Takechi K; Yanagawa H; Zamami Y; Ishizawa K; Tanaka A; Araki H
Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381
[TBL] [Abstract][Full Text] [Related]
46. Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations.
Frazee EN; Kuper PJ; Schramm GE; Larson SL; Kashani KB; Osmon DR; Leung N
Antimicrob Agents Chemother; 2012 Dec; 56(12):6181-5. PubMed ID: 22985887
[TBL] [Abstract][Full Text] [Related]
47. Acute Kidney Injury Associated With Vancomycin When Laxity Leads to Injury and Findings on Kidney Biopsy.
Katikaneni M; Lwin L; Villanueva H; Yoo J
Am J Ther; 2016; 23(4):e1064-7. PubMed ID: 26035034
[TBL] [Abstract][Full Text] [Related]
48. New target concentrations for vancomycin in Hong Kong.
You JH; Chow SS; Lui JW; Ip M
Int J Antimicrob Agents; 2011 Jan; 37(1):83-4. PubMed ID: 21074378
[No Abstract] [Full Text] [Related]
49. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients.
Madigan T; Sieve RM; Graner KK; Banerjee R
Pharmacotherapy; 2013 Dec; 33(12):1264-72. PubMed ID: 23864541
[TBL] [Abstract][Full Text] [Related]
50. Predictive Performance of Vancomycin Trough Concentrations in Patients With Diabetes With Microalbuminuria.
Kimura H; Shigematsu M; Tanaka A; Watanabe S; Takatori S; Tanaka M; Mizuma T; Araki H
Ther Drug Monit; 2017 Dec; 39(6):614-616. PubMed ID: 28976419
[TBL] [Abstract][Full Text] [Related]
51. Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring.
Balch AH; Constance JE; Thorell EA; Stockmann C; Korgenski EK; Campbell SC; Spigarelli MG; Sherwin CM
J Clin Pharmacol; 2015 Feb; 55(2):212-20. PubMed ID: 25264036
[TBL] [Abstract][Full Text] [Related]
52. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
[TBL] [Abstract][Full Text] [Related]
53. Vancomycin dosing and target attainment in children.
Hwang D; Chiu NC; Chang L; Peng CC; Huang DT; Huang FY; Chi H
J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
[TBL] [Abstract][Full Text] [Related]
54. Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome.
McNeil JC; Kok EY; Forbes AR; Lamberth L; Hulten KG; Vallejo JG; Mason EO; Kaplan SL
Pediatr Infect Dis J; 2016 Mar; 35(3):263-8. PubMed ID: 26646549
[TBL] [Abstract][Full Text] [Related]
55. Vancomycin trough concentrations in overweight or obese pediatric patients.
Heble DE; McPherson C; Nelson MP; Hunstad DA
Pharmacotherapy; 2013 Dec; 33(12):1273-7. PubMed ID: 23798327
[TBL] [Abstract][Full Text] [Related]
56. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
Fusco NM; Toussaint KA; Prescott WA
Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
[TBL] [Abstract][Full Text] [Related]
57. Impact of model-informed precision dosing on achievement of vancomycin exposure targets in pediatric patients with cystic fibrosis.
Frymoyer A; Schwenk HT; Brockmeyer JM; Bio L
Pharmacotherapy; 2023 Oct; 43(10):1007-1014. PubMed ID: 37401162
[TBL] [Abstract][Full Text] [Related]
58. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
Joo J; Yamaki J; Lou M; Hshieh S; Chu T; Shriner KA; Wong-Beringer A
Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
[TBL] [Abstract][Full Text] [Related]
59. Pitfalls in dosing vancomycin.
Koppula S; Ruben S; Bangash F; Szerlip HM
Am J Med Sci; 2015 Feb; 349(2):137-9. PubMed ID: 25437128
[TBL] [Abstract][Full Text] [Related]
60. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices.
Jeffres MN; Isakow W; Doherty JA; McKinnon PS; Ritchie DJ; Micek ST; Kollef MH
Chest; 2006 Oct; 130(4):947-55. PubMed ID: 17035423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
